![François Liebaert](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
François Liebaert
Geen lopende functies
Loopbaan van François Liebaert
Eerdere bekende functies van François Liebaert
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | Operationeel Directeur | - | - |
INTEGRAGEN | Hoofd Techniek/Wetenschap/O&O | 22-09-2011 | - |
Opleiding van François Liebaert
Université de Lille II | Doctorate Degree |
École des Hautes Études Commerciales de Paris | Masters Business Admin |
Statistieken
Internationaal
Frankrijk | 5 |
Operationeel
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Masters Business Admin | 1 |
Sectoraal
Consumer Services | 3 |
Health Services | 2 |
Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
INTEGRAGEN | Health Services |
Bedrijven in privébezit | 1 |
---|---|
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | Health Technology |
- Beurs
- Insiders
- François Liebaert
- Ervaring